Medico Reach

OCTOBER 17, 2022

However, this can lead to several issues, such as: Implantation resistance due to reactionary metabolism Allergic reactions to the nickel component found in stainless steel composites Widespread bone destruction due to immunological responses to cobalt particles. billion by 2029. The US-based Enovis is leading this new development.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98

Medico Reach

OCTOBER 17, 2022

However, this can lead to several issues, such as: Implantation resistance due to reactionary metabolism Allergic reactions to the nickel component found in stainless steel composites Widespread bone destruction due to immunological responses to cobalt particles. billion by 2029. The US-based Enovis is leading this new development.

Medical 52

Medical Food and Drug Administration Healthcare Healthcare 52

Pharmaceutical Technology

APRIL 4, 2023

While Scorpion will lead the development of STX-721, Pierre Fabre will handle STX-241. The Boston, Massachusetts-based Scorpion expects to submit an investigational new drug (IND) application for STX-721 to the US Food and Drug Administration (FDA) in mid-2023, with an IND application for STX-241 expected in H1 2024.

Food and Drug Administration 52

Food and Drug Administration Biopharma FDA Pharmaceutical 52

Pharmaceutical Technology

MAY 17, 2023

The US Food and Drug Administration (FDA) has awarded an orphan drug designation to Intercept Pharmaceuticals’ fixed-dose combination of obeticholic acid and bezafibrate for the treatment of primary biliary cholangitis. This results in bile buildup in the liver and can lead to scarring. billion in 2029.

Food and Drug Administration 52

Food and Drug Administration FDA Pharmaceutical Prospecting 52